Table 5.

Characteristics of LVAD Implantation in Patients With a Prior COVID-19 infection

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Demographics
Age, years	56	64	59	47	61	61
Sex	M	M	M	F	M	M
BMI	37.2	31.6	30.0	31.0	19.4	21.9
Race/Ethnicity	Black	White	Black	Black	Hispanic	Black
Blood group	O	A	O	A	O	B
Medical characteristics
Hypertension	Yes	Yes	Yes	Yes	Yes	Yes
Diabetes mellitus	Yes	Yes	No	Yes	No	No
Lung disease	Yes	No	Yes	No	No	Yes
Smoking history	No	Yes	No	Yes	Yes	Yes
Chronic kidney disease stage ≥3	No	Yes	Yes	Yes	Yes	No
Prior stroke	Yes	No	No	No	No	No
INTERMACS profile	3	3	3	3	3	3
LVAD device	HM3	HM3	HM3	HM3	HM3	HM3
LVAD intention (BTT or DT)	DT	DT	DT	DT	DT	DT
Time from +SARS-CoV-2 PCR to LVAD, days	7	20	132	18	61	194
Supplemental oxygen	Yes	No	No	No	No	Ukn
Post-LVAD outcomes
Duration on LVAD support, days (IQR)	194	33	172	243	45	140
Days from LVAD surgery to discharge	50	30	71	55	16	73
Days from LVAD surgery to extubation	7	30	38	14	3	14
Tracheostomy	No	Yes	Yes	No	No	No
RVAD support	Yes	No	No	Yes	No	No
CRRT	Yes	Yes	Yes	Yes	No	No
Renal Recovery	Yes	Yes	Yes	Yes	–	–
Stroke	No	Yes	No	Yes	No	Yes
Pump thrombosis/malfunction	No	No	No	No	No	No
Alive at end of follow up	Alive	Deceased	Alive	Alive	Alive	Alive

BTT, bridge to Transplant; CRRT, continuous renal replacement therapy; DT, destination therapy.